Skip to main content

Table 1 Baseline characteristics of the subjects enrolled in the present study

From: High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome

 

All

NC group

SAP group

ACS group

Number

138

19

41

78

Age, years

65 ± 1 (40–86)

65 ± 2 (51–79)

65 ± 1 (49–81)

65 ± 1 (40–86)

Body mass index, kg/m2

24.3 ± 0.3 (17.7-38.4)

24.3 ± 1.0 (19.5-32.5)

24.6 ± 0.6 (17.7-31.2)

24.2 ± 0.4 (17.8-38.4)

Visceral fat area, cm2

117 ± 5 (25–223)

101 ± 13 (25–223)

125 ± 10 (17–277)

116 ± 6 (18–259)

Subcutaneous fat area, cm2

130 ± 5 (22–361)

124 ± 15 (45–329)

142 ± 8 (50–224)

126 ± 7 (22–361)

Smoking (none-/ex-/current-smoker), n

45/32/61

9/5/5

14/10/17*

22/17/39

Diabetes mellitus, n

69 (50%)

10 (53%)

29 (71%)

30 (38%)

sulfonyl ureas/glinides/biguanides/alpha glucosidase inhibitors/Insulin, n

22/5/10/20/6

5/0/1/2/2

10/5/8/2/2

7/0/1/16/2

Hypertension, n

92 (67%)

15 (79%)

27* (66%)

50 (64%)

calcium channel antagonists/angiotensin receptor blockers /β-blockers/diuretics, n

44/70/62/9

7/2/2/0

21/20/4/4

16/48/56/5

Dyslipidemia, n

61 (44%)

7 (37%)

24* (59%)

30 (38%)

Statins/fibrates/ezetimibe/cholestimide, n

83/2/1/1

10/1/0/0

10/0/1/1

63/1/0/0

anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n

115/32/65

6/0/4

31/0/20

78/32/41

Family history of CAD, n

13 (9%)

2 (11%)

3* (7%)

8 (10%)

Systolic blood pressure, mmHg

138 ± 2 (90–217)

139 ± 4 (108–173)

138 ± 3 (100–175)

138 ± 3 (90–217)

Diastolic blood pressure, mmHg

83 ± 1 (49–146)

79 ± 2 (64–94)

75 ± 2 (49–99)

87 ± 2 (57–146)

Hemoglobin A1c (NGSP), %

6.7 ± 0.1 (3.4-12.2)

7.3 ± 0.4 (5.8-9.8)

6.9 ± 0.2 (5.5-10.1)

6.6 ± 0.2 (3.4-12.2)

LDL-C, mg/dL

112 ± 3 (20–250)

114 ± 8 (58–154)

107 ± 6 (49–197)

115 ± 4 (20–250)

Triglyceride, mg/dL

122 ± 7 (24–611)

124 ± 16 (49–263)

140 ± 12 (59–374)

113 ± 10 (24–611)

HDL-C, mg/dL

49 ± 1 (26–128)

63 ± 4 (39–95)

53 ± 3 (27–104)

44 ± 2 (26–128)¶,†

Creatinine, mg/dL

0.85 ± 0.03 (0.47-1.34)

0.86 ± 0.04 (0.60-1.20)

0.85 ± 0.03 (0.60-1.30)

0.91 ± 0.04 (0.47-1.34)

Target lesions (LMCA/LAD/LCX/RCA), n

2/64/20/33

-

2/20/14/5

0/44/6/28

Vessels (None/SVD/DVD/TVD), n

19/72/32/15

-

0/22/14/5

0/50/18/10

Procedures (PCI/CABG), n

118/1

-

40/1

78/0

  1. Data are mean ± SEM (range), or number of subjects analyzed. *P < 0.05, Compared with the NC group, P < 0.0001, Compared with the NC group, P < 0.001, Compared with the SAP group.
  2. Differences among groups were compared by one- or two-way analysis of variance (ANOVA) with Fisher's protected least significant difference test for multiple-group analysis. Differences in frequencies were examined by the χ2 test. CAD, Coronary artery disease; HDL-C, High-density lipoprotein-cholesterol; LDL-C, Low-density lipoprotein-cholesterol; LMCA, Left main coronary artery; LAD, Left anterior descending artery; LCX, Left circumflex artery; RCA, Right coronary artery; SVD, Single vessel disease; DVD, Double vessels disease; TVD, Triple vessels disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass graft.